Chesterbrook-based Trevena and Wayne-based Aclaris Therapeutics have joined the growing list of drug developers currently working on potential COVID-19 treatments, writes John George for the Philadelphia Business Journal.
Trevena is working with Imperial College London to evaluate the potential of one of its former drug candidates in patients with COVID-19.
Imperial College is sponsoring and funding a study of TRV027 – a drug candidate Trevena studied for acute decompensated heart failure – as a treatment for acute lung injury that contributes to acute respiratory distress syndrome in patients who contracted COVID-19.
“The COVID-19 infection causes things to be out of balance,” said Trevena CEO Carrie Bourdow. “The Imperial College study will look at how effectively TRV027 can restore that balance, repair damage to the lungs, and eliminate blood clots from developing.”
The study of the potential treatments is receiving additional support from the British Heart Foundation Centre for Research Excellence.
Meanwhile, Aclaris Therapeutics is supporting an investigator-initiated trial of ATI-450 – a drug it is developing on rheumatoid arthritis – for cytokine release syndrome.
The company is providing funding and clinical drug supply to research at the University of Kansas Medical Center, which is sponsoring the trial.
Read more in the Philadelphia Business Journal here.
You Might Also Like